Specialized Diagnostics Leverage OncoOmicsDx focus on comprehensive tumor profiling using mass spectrometry and multi-omics from FFPE tissue to position cross-sell opportunities with broader genomic testing and targeted therapy alignment for cancer centers seeking integrated workflows.

CAP CLIA Advantage Highlight the unique CAP-accredited, CLIA-certified status as a quality and compliance differentiator to win contracts with hospitals and outpatient labs that require stringent validation and regulatory alignment for actionable molecular diagnostics.

Integrated Sample Utility Offer bundled solutions that maximize biopsy value by combining proteomic quantitation with next-generation sequencing from the same sample, enabling faster turnaround and reducing tissue waste—a compelling value prop for surgical oncologists and pathology labs.

Growth Readiness With revenue in the low to mid-range and an established lab infrastructure, target mid-market hospitals and cancer centers looking to expand their molecular testing capacity without large capital expenditure, offering scalable service partnerships.

Industry Alignment Position alongside large peers in oncology diagnostics by emphasizing proprietary solubilization and mass spectrometry capabilities as a differentiator for complex tumor profiling, opening discussions with health systems pursuing advanced precision medicine programs.